For laboratory research use only. Not for human or veterinary use.

Demonstration data. Every lot code, purity figure, chromatogram, certificate, laboratory and date on this site is a sample for design review. None of it is a real measurement.
Skip to content
QualityVerifyResearch CenterWholesaleAboutPartner with usSupportContact Shop

Retatrutide

A triple-receptor agonist peptide (GIP, GLP-1, and glucagon receptors), currently investigational and not FDA-approved.

Research Article Compound Hubs 2 min read

Mechanism

One molecule, three receptors

Retatrutide is a single synthetic peptide reported to act at three separate receptors. This is what published research describes at each one.

Step 1 Synthetic peptide · LY3437943

Retatrutide

One molecule. What is under study is that it acts at three receptors rather than one.Schematic diagram: a peptide backbone drawn as beads on a curve, labelled Retatrutide, a single synthetic peptide studied at three receptors. The drawing is a schematic and does not depict a molecular structure.CompoundRetatrutideA single peptide studied at three receptors
One molecule. What is under study is that it acts at three receptors rather than one. Hold any part of the figure to follow its route Press and hold any part of the figure to follow its route Schematic backbone. Bead count is illustrative. This is not a structural depiction.

What you're seeing

A laboratory-made peptide designed to act on three different receptors at once, rather than one. It is investigational: it has not been approved for any use.

Scientific detail

Described in the literature as a triple receptor agonist peptide, developed under the code LY3437943. An agonist is a molecule that binds a receptor and activates it. Acting at three receptors with one molecule is the property being studied here; single-receptor and dual-receptor agonists are separate, earlier classes of compound.

Terminology What are receptors, ligands, agonists, and antagonists? What is a peptide, and how is it different from a protein?

Source Coskun T. et al. — LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist: from discovery to clinical proof of concept (Cell Metabolism, 2022)

Step 2 In a cell membrane

Where a receptor sits

All three receptors here are built the same way: they span a cell membrane, and binding on the outside starts a signal on the inside.Cross-section diagram: a cell membrane drawn as a lipid bilayer with a seven-transmembrane receptor set into it. Above the membrane is where the hormone arrives; below it is where the signal goes. All three of this compound's receptors share this architecture.Where a receptor sitsOutside the cellhormone arrivesInside the cellsignal continuesShared by all three receptors
All three receptors here are built the same way: they span a cell membrane, and binding on the outside starts a signal on the inside. Schematic cross-section. The helices are the shared seven-transmembrane architecture of this receptor family, not a resolved structure.

What you're seeing

A receptor is not free-floating. It spans the wall of a cell, so that something arriving on the outside can start a signal on the inside. All three receptors here are built that way.

Scientific detail

GLP-1R, GIPR and the glucagon receptor are G-protein-coupled receptors with a seven-transmembrane architecture: seven segments crossing the membrane, an outward-facing side that binds, and an inward-facing side that signals. That shared architecture is why one molecule can be studied at all three. The drawing is a schematic of that arrangement, not a resolved structure.

Terminology What are receptors, ligands, agonists, and antagonists?

Source Coskun T. et al. — LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist: from discovery to clinical proof of concept (Cell Metabolism, 2022)

Step 3 GLP-1 receptor

GLP-1R

The best-established of the three, and the mechanism behind an existing, widely studied drug class.Profile card: GLP-1R, the glucagon-like peptide-1 receptor, drawn as a filled node. Its natural signal is GLP-1, a gut hormone released in response to food; it belongs to blood-sugar regulation and appetite signaling; it is the best established of the three receptors.ReceptorGLP-1RGLP-1 receptorNatural signalGLP-1, a gut hormoneIn the bodyBlood sugar and appetiteBest established of the three
The best-established of the three, and the mechanism behind an existing, widely studied drug class.

What you're seeing

The receptor for GLP-1, a gut hormone involved in blood-sugar regulation and appetite signaling. It is the best-established of the three, and the mechanism behind an existing, widely studied drug class.

Scientific detail

Glucagon-like peptide-1 receptor. In the published discovery pharmacology, in-vitro activity at this receptor was reported as balanced with activity at the glucagon receptor. Reduced calorie intake in preclinical models was attributed to GLP-1 and GIP receptor activity.

Terminology What are receptors, ligands, agonists, and antagonists?

Source Coskun T. et al. — LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist: from discovery to clinical proof of concept (Cell Metabolism, 2022)

Step 4 GIP receptor

GIPR

A second gut-hormone receptor. Whether adding it changes the picture meaningfully is an open research question.Profile card: GIPR, the GIP receptor, drawn as an open ring. Its natural signal is GIP, a gut hormone released after eating; it is being studied for effects that may add to GLP-1 receptor activity; whether it changes the picture meaningfully is an open research question.ReceptorGIPRGIP receptorNatural signalGIP, released after eatingIn the bodyMay add to GLP-1R activity — stillunder studyStill an open research question
A second gut-hormone receptor. Whether adding it changes the picture meaningfully is an open research question.

What you're seeing

The receptor for GIP, another gut hormone released after eating. It is being studied for effects that may add to, or differ from, GLP-1 receptor activity.

Scientific detail

Glucose-dependent insulinotropic polypeptide receptor. The discovery pharmacology reported greater in-vitro activity at this receptor than at the other two. Whether combined GIP and GLP-1 receptor activity is meaningfully different from GLP-1 receptor activity alone is an active research question, not a settled one.

Terminology What are receptors, ligands, agonists, and antagonists?

Source Coskun T. et al. — LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist: from discovery to clinical proof of concept (Cell Metabolism, 2022)

Step 5 Glucagon receptor

GCGR

The third receptor, and the one that distinguishes this compound from dual-receptor agonists.Profile card: the glucagon receptor, GCGR, drawn as a ring broken at the top. Its natural signal is glucagon, a hormone that mobilises stored energy; it belongs to how the body uses stored energy; it is the component that distinguishes this compound from dual-receptor agonists.ReceptorGlucagon receptorGCGRNatural signalGlucagonIn the bodyHow the body uses stored energyThe distinguishing receptor
The third receptor, and the one that distinguishes this compound from dual-receptor agonists.

What you're seeing

The receptor for glucagon, a hormone involved in how the body uses stored energy. It is the component that distinguishes this compound from dual-receptor agonists.

Scientific detail

In the cited preclinical work, glucagon-receptor activity was associated with increased energy expenditure, reported alongside the reduced calorie intake attributed to the other two receptors. This describes what that study measured in its models. It is not a predicted result in a person.

Terminology What are receptors, ligands, agonists, and antagonists? How does research move from a lab bench to a clinical trial, and why do results sometimes not translate?

Source Coskun T. et al. — LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist: from discovery to clinical proof of concept (Cell Metabolism, 2022)

Step 6 What is under study

Triple-receptor agonism

Three receptors, one molecule. The research question is whether that behaves differently from activating one or two — not that it must.Network map: retatrutide sits at the centre, connected out to three separate receptors — GLP-1R drawn as a filled node, GIPR as an open ring, and the glucagon receptor as a broken ring — with light links drawn between the receptors. The three connections converge on an open research question that trials are still answering.Receptor networkRetatrutideGLP-1RGIPRGlucagon RStill being answered in trials
Three receptors, one molecule. The research question is whether that behaves differently from activating one or two — not that it must. More receptors is a mechanism, not a promise of a larger result in a person.

What you're seeing

The research question is whether activating all three receptors with one molecule behaves differently from activating one or two. That question is still being answered in clinical trials.

Scientific detail

A phase 1b trial in adults with type 2 diabetes and a phase 2 trial in adults with obesity have been published, and a phase 3 program is registered on ClinicalTrials.gov. A published trial result is evidence; it is not the same thing as an approved use, which follows full regulatory review.

Terminology How does research move from a lab bench to a clinical trial, and why do results sometimes not translate?

Source LY3437943 in people with type 2 diabetes: a phase 1b multiple-ascending-dose trial (The Lancet, 2022) Triple-Hormone-Receptor Agonist Retatrutide for Obesity — a phase 2 trial (2023) TRIUMPH-1 phase 3 study record, NCT05929066 (ClinicalTrials.gov)

That is the mechanism in brief. The rest of this page is the detail.

View Retatrutide Verify a lot

Keep going

Go deeper into the science.

Discover the compounds, pathways and research systems connected to what you're already exploring.

Adjacent research pathways

  • Tesamorelin

    For research use only. Not for human consumption.

    20 mg $149.00

    Explore a different side of metabolic and endocrine research through the GHRH and GH/IGF-1 axis.

    Explore the science View product

  • Ipamorelin

    For research use only. Not for human consumption.

    10 mg $109.00

    Explore ghrelin-receptor signaling and growth-hormone release in a separate but related research context.

    Explore the science View product

Research systems Metabolic pathways Endocrine signaling

These are separate research materials with separate research records. Nothing here suggests combining them, and no connection above is a claim about using more than one.

Simplified pathway, drawn for educational purposes. It shows what published research describes about the molecule. It does not describe a result in a person, and it is not a claim about NuePharma material.

What research has established

  1. Preclinical research Published

    The discovery pharmacology characterised activity at all three receptors in vitro and studied the compound in animal models, where glucagon-receptor activity was associated with increased energy expenditure alongside reduced calorie intake attributed to the other two receptors.

    Source Coskun T. et al. — LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist: from discovery to clinical proof of concept (Cell Metabolism, 2022)

  2. Human research Published

    A phase 1b multiple-ascending-dose trial in adults with type 2 diabetes and a phase 2 trial in adults with obesity have both been published, and a phase 3 program is registered and under way.

    Source LY3437943 in people with type 2 diabetes: a phase 1b multiple-ascending-dose trial (The Lancet, 2022) Triple-Hormone-Receptor Agonist Retatrutide for Obesity — a phase 2 trial (2023) TRIUMPH-1 phase 3 study record, NCT05929066 (ClinicalTrials.gov)

  3. Regulatory status Not approved

    Investigational. Not approved by the FDA for any indication, in any population. A published trial result is evidence; approval follows full regulatory review, and that has not happened.

    Source TRIUMPH-1 phase 3 study record, NCT05929066 (ClinicalTrials.gov)

Sources for this diagram

  1. Coskun T. et al. — LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist: from discovery to clinical proof of concept (Cell Metabolism, 2022)
  2. LY3437943 in people with type 2 diabetes: a phase 1b multiple-ascending-dose trial (The Lancet, 2022)
  3. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — a phase 2 trial (2023)
  4. TRIUMPH-1 phase 3 study record, NCT05929066 (ClinicalTrials.gov)

Overview. Retatrutide (development code LY3437943) is a synthetic peptide developed by Eli Lilly and Company, in active clinical development. It is not an approved pharmaceutical product; the material in NuePharma’s catalog is supplied strictly for research use only, and is not the pharmaceutical product used in Eli Lilly’s clinical trials.

Molecule / class. Retatrutide is described in the scientific and clinical-trial literature as a triple receptor agonist peptide.

Mechanism under investigation. It is designed to simultaneously activate three receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. A dual agonist activates two of these mechanisms; a single-receptor agonist activates one. Researchers are studying combined activity across all three because each receptor is independently linked to different aspects of glucose and energy metabolism, and combining them is hypothesized to produce effects distinct from targeting any one receptor alone — see the terminology hub for what “receptor” and “agonist” mean generally.

Why the pathway is researched. GLP-1 receptor activity is the mechanism behind an established, widely studied drug class; GIP and glucagon receptor activity are being studied for potential additive or complementary metabolic effects. This is an active area of pharmaceutical research, not a settled question.

Human research. As of the most recent publicly reported results, retatrutide has completed a major Phase 3 trial (TRIUMPH-1, registered on ClinicalTrials.gov) studying its effect in adults with obesity or overweight, and is in Phase 3 study for several additional conditions, including type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, and cardiovascular and kidney outcomes. Reported topline results describe substantial average weight loss at the highest studied dose over roughly 80 weeks, though full peer-reviewed publication and regulatory review are what ultimately establish an approved use, not a topline announcement.

Regulatory status. Retatrutide is not FDA-approved. It remains an investigational compound, meaning its safety and effectiveness for any use are still under formal review, not yet officially established the way an approved medicine’s are. NuePharma’s RUO material is not equivalent to, and is not derived from, the material used in Eli Lilly’s clinical trials.

What remains unknown. Long-term safety and effectiveness data, the final approved indication and dosing (if approval occurs), and how findings from controlled trial populations generalize more broadly are all still being established through the ongoing trial program.

NuePharma product information. NuePharma’s Retatrutide listing is 15 mg per vial, supplied lyophilized, for research use only.

Sources & further reading

Verify a lot

Related

Back to the Research Center

Back to the product

Every unit of this compound traces to a lot, and every lot to its own analytical record.

View Retatrutide Verify a lot

Can't find your answer?

Order / product / documentation

support@nuepharmahealth.com

Contact support

Wholesale

Wholesale inquiry

Business / media / creator / partnerships

hello@nuepharmahealth.com

Contact NuePharma

Verify

Verify a lot